Summary Among a cohort of 10,106 three-year survivors of childhood cancer, 90 second primary tumours (SPTs) were observed. Within 25 years of 3-year survival about 4% developed a SPT, about 6-fold expected, the relative risk not varying much with increasing follow-up.
At least half of the children who develop cancer now survive beyond three years (Stiller, pers. comm.); thus we expect in excess of 600 such survivors each year from among individuals currently treated in Britain. The intensive therapy given to achieve the improvement in survival contributes towards late effects generally, and second primary tumours in particular. The duration of survival for many individuals includes the latent periods characteristic of radiation and chemical carcinogenesis (Boice, 1981 ; Committee on the Biological Effects of Ionizing Radiation, 1980; International Agency for Research on Cancer, 1981; Schmahl et al., 1982) . Furthermore since individuals are initially treated when young there is less opportunity for other environmental factors to be important in the development of second tumours.
We examine the incidence of second primary tumours (SPTs) within a well defined cohort of three-year survivors of childhood cancer treated in Britain between 1940 and 1979. In the accompanying paper (Kingston et al., 1987) we examine the relationship between first and second primary tumours in our complete register of multiple primary tumour cases, all of whom developed at least two distinct primary tumours, at least one of these being diagnosed before age 15; this group includes cases excluded from the cohort. Childhood cancer registration is estimated to include over 90% of incident cases (Stiller, 1985; Draper et al., 1982) . In addition a series of three-year survivors diagnosed before 1962 was constructed from case-lists, when they were known to be complete, covering specific years of diagnosis at particular registries or treatment centres, extending back to 1940 for some centres. There are just under 2,000 such threeyear survivors included among the total of about 10,000.
Materials and methods

Ascertainment
Cases were selected if diagnosed in 1979 or earlier and routinely ascertained, as above, through their first primary tumour (FPT). Follow-up with respect to SPT was achieved by 'flagging' almost all survivors at the National Health Service Central Registers, and through the routine receipt of cancer registrations below age 15. 'Flagging' an individual at NHSCR ensures the automatic notification of deaths registered at any time and of cancer registrations from 1971 onwards. In addition, positive medical follow-up was available for most cases through hospital records, general practitioners and cancer registries. Furthermore, all death certificates for deaths from neoplasia occurring before age 20 in Britain are received by the CCRG and routinely checked for evidence of multiple tumours. The study end-point for almost all cases not dying, emigrating or lost to follow-up was 31 December 1981. For the remainder the study endpoint was the most recent date available through positive follow-up or the routine receipt of cancer registrations below age 15. SPTs were included in the incidence calculations provided they occurred before the study end-point. Confirmation that very few second primary tumours have been missed is provided by a separate study that involved writing to the general practitioners of 2,000 of the surviving cases in the present study and asking specifically about other primary tumours. No additional SPTs were identified by this independent study. We restrict attention to the incidence of SPTs among three-year survivors; this excludes the three years immediately after diagnosis when therapeutic influences are less likely to contribute towards the development of a subsequent tumour, and where recurrence and metastatic spread are much more common.
In general, both the first and second primary tumour were required to be malignant or intracranial to be included. However, non-melanoma malignant skin tumours were excluded from the relative risk calculations because of the known incompleteness of ascertainment in the general population and the suspected substantially better ascertainment among cases already having suffered a FPT. When an individual is suspected to have had multiple primary tumours the diagnoses of both the first and second tumours have, in over 90% of cases, been confirmed by review of the relevant pathological material. For a few cases, almost always brain tumours or retinoblastoma, where no histological material was available, confirmation of the diagnosis was based on a review of radiological or clinical evidence or both.
For tumours other than retinoblastoma treatment information was obtained from hospital and general practitioner records when readily available, but was only obtained in relation to initial treatment. Therefore treatment information for recurrence occurring a substantial time after initial treatment will have been missed.
Statistical methods
The method used to compare the observed number of subsequent primaries with those expected was based on the assumption that the observed number of second primaries approximated a Poisson distribution. Test of significance and confidence intervals for the relative risk of a SPT were based on exact Poisson probabilities since the numbers of events are small. Expected numbers of subsequent cancers were estimated by applying age/sex specific rates derived from cancer registration statistics (Office of Population Censuses and Surveys, 1983) to the person-years accumulated in the corresponding age/sex specific categories. The cumulative probability of a second primary tumour was estimated using standard Kaplan-Meier procedures described by Peto et al. (1977) ; comparison of the cumulative risks of SPT for different subgroups was carried out using standard tests (Peto et al., 1977) .
A measure of inherent risk was based on SPTs occurring among all individuals treated with neither radiotherapy nor chemotherapy; it is therefore a measure of the risk of SPT in the absence of radiotherapy or chemotherapy. It is possible that those selected for radiotherapy or chemotherapy with a particular tumour are more prone to SPTs than those not so treated. It is impossible to examine this possibility with the present data.
Results
Classification of tumours
A total of 10,106 cases satisfied all criteria required for inclusion as a FPT; 90 of these developed a second primary tumour satisfying all conditions necessary for inclusion in incidence estimates. A cross-tabulation of the SPT cases is given in Table I ; the rows correspond to different FPT groups classified according to morphology (World Health Organisation, 1976) . The columns correspond to the different SPT groups classified firstly by site of tumour (World Health Organisation, 1969) , and secondly classified by morphology. The extreme right hand column of Table I gives the total number of three-year survivors at risk of a SPT after each initial tumour type.
The comparison with expected incidence is restricted to SPTs with an ICD-8 code within the range SPTs after all initial tumour types Of the 10,106 three-year survivors 7,871 were followed up to the end-point of the study, 31 December 1981; 2,235 were either censored (death, emigration or lost to follow-up) or were diagnosed with a SPT before the study end-point. For six of these cases no follow-up was available.
The estimates of relative risk of a second tumour after all FPTs considered together are given in Table II 
SPTs after retinoblastoma
We classify unilateral cases known to be familial and bilateral cases as 'genetic', unilateral cases with no evidence of family history as 'non-genetic'. In contrast to the generality of cases included in the cohort, individuals with retinoblastoma have been followed-up much more intensively, since they have formed the basis of a separate detailed study (Draper et al., 1986) increased risk of SPTs generally and osteosarcoma in particular following radiotherapy without chemotherapy compared to that following neither radiotherapy nor chemotherapy. Furthermore there is suggestive evidence that the risks of SPTs generally, and osteosarcoma in particular, are increased following radiotherapy and chemotherapy (almost always cyclophosphamide in this series) compared to those given radiotherapy but no chemotherapy. However, cases given chemotherapy were also more likely to have had more than one course of radiotherapy and radioactive implants. Thus although there is some evidence of an increased risk of SPT associated with the use of cyclophosphamide, this may be due to cyclophosphamide, radiotherapy or an interaction between them. For a more detailed examination of the associations between risk of SPT and therapy the reader should consult our more detailed papers on retinoblastoma (Draper et al., 1986; Hawkins, 1987) .
SPTs after all FPTs except retinoblastoma For the sub-cohort of all FPTs except retinoblastoma we give, in Table V , the numbers of three-year survivors at risk following treatment with radiotherapy, chemotherapy, both and neither of these forms of therapy. Two important considerations are illustrated by Table V. Firstly there is a relatively small number of SPTs after chemotherapy and thus we are unable to examine the risk of SPT associated with chemotherapy in much detail following specific FPTs. This arises from the relatively recent widespread use of chemotherapy, and, given the current study end-point, average follow-up times are short. The mean follow-up times beyond three years for those having received neither radiotherapy nor chemotherapy, radiotherapy but no chemotherapy and both radiotherapy and chemotherapy following FPTs other than retinoblastoma were 9.5, 9.8 and 3.8 years respectively (see Table VII ).
The second general point illustrated by Table V follows from the large category of cases with no record of whether radiotherapy or chemotherapy were given. Comparisons between different treatment subgroups must be undertaken carefully since the records of a patient who develops a SPT are pursued with much greater effort than are those for cohort members not developing a SPT; as a result we know the details with regard to both radiotherapy and chemotherapy for all but one of the patients developing a SPT. In all we observed six-fold the number of malignant SPTs expected and about twenty-fold the number of malignant bone tumours expected; four were osteosarcomas arising within tissue directly irradiated. There were seven malignant digestive tract tumours observed among all three-year survivors excluding retinoblastoma, six of these occurring among those given radiotherapy but not chemotherapy; within this treatment subgroup this represents fifteen-fold the number expected. None of these individuals was known to have genetic conditions predisposing to neoplasia. Furthermore three of these digestive tract SPTs arose within directly irradiated tissue. Three second primary leukaemias developed following radiotherapy but no chemotherapy; this represents five-fold the number expected.
There is no clear systematic variation in relative risk with increasing follow-up.
Risk of SPT in relation to radiotherapy and chemotherapy The mean follow-up period following both radiotherapy and chemotherapy was substantially less than for those with treatments not involving chemotherapy, Table VII; therefore our results necessarily apply to this shorter interval. The cumulative risk of a SPT by ten years from three-year survival was under 1%, Table VII. The observed number of subsequent malignant tumours was about ten-fold expected. However, this was reduced to four-fold expected with inclusion of all the possible 'no record' cases. The observed number of subsequent primary leukaemias was five to tenfold expected depending on whether the 'no record' cases were included or excluded.
SPTs after CNS tumours
The cumulative risk of a SPT by twenty years from threeyear survival is 2.4% (SE =1.1%). However, because of the occurrence of many SPTs after twenty years this rises to 5.1 % (SE= 3.7%) by 25 years from three-year survival. Relative risks of subsequent malignant tumour are reported in Table  VIII ; seventeen SPTs were observed, 3.37 expected, yielding a relative risk of about five. There was a larger than expected number of both malignant connective tissue and thyroid tumours. The relative risk of a SPT among these patients is about ten after a decade from diagnosis and again there is no evidence of decline in the relative risk with increased survival time.
SPTs after Wilms' tumour The cumulative risk of a SPT by 20 years from three-year survival is 3.1% (SE= 1.9%). The relative risk of a subsequent malignant tumour was (RR = 8, 95%CI = 3, 16). SPTs after leukaemia Only three SPTs, all CNS, were observed, though the mean follow-up period beyond three-years was only 3.4 years. As a consequence our results following leukaemia are very provisional. Nevertheless the number of subsequent malignant CNS tumours observed was about twenty-fold expected.
Discussion
It is not the purpose of the present study to examine the relationship between risk of SPT and treatment in detail; this will be undertaken in a case-control study in which exhaustive efforts will be made to obtain all treatment information. However, we examine this relationship in rather broad terms.
It is very difficult to compare the overall risk from different series because of the many confounding factors, including: different series compositions with regard to the initial childhood cancers, different treatments, different entry to risk points, different follow-up methods and assumptions and different average follow-up periods. However, we shall attempt to compare the overall risks in general terms. In our series the estimated cumulative probability of SPT by 25 years from three-year survival was about 4%, the relative risk of a SPT was about six corresponding to an average follow-up period of about eight years from three-year survival. The relative and cumulative risks of a SPT were estimated to be substantially higher in the reports from the Sidney Farber Cancer Institute (SFCI) series (Li et al., 1975; Li, 1977) : a relative risk of over twenty among five-year survivors was reported, the cumulative probability of a second malignancy was estimated to be 12% (SE=4%) by twenty years from five-year survival; among those who received orthovoltage radiotherapy the cumulative risk of a second primary cancer within the radiation field was 17% (SE = 6%) twenty years from five-year survival. The latest incidence report from the Late Effects Study Group (LESG) (Tucker et al., 1984) gives a relative risk of fifteen corresponding to an average follow-up of 5.5 years; the cumulative risk was estimated to be 12% by 25 years from diagnosis. Even in the initial report on incidence from LESG (Mike et al., 1982) where retinoblastoma was specifically excluded, the risks are no smaller than in our study. The risks from the University of Minnesota series of children treated with megavoltage radiotherapy (Potish et al., 1985) were higher than in our series but they include many benign tumours that we would exclude from consideration.
The relative risk of SPT remained fairly constant with time survived in our series, six-fold expected, for the first 30 years following three-year survival after childhood cancer. There is no evidence of the risk diminishing with increasing time from diagnosis; this is in agreement with Tucker et al. (1984) .
Radiotherapy was considered to have contributed substantially towards the excess of second tumours observed in the LESG, SFCI and the University of Minnesota series. The increased risk of SPTs in relation to radiotherapy compared to inherent risk in our study provides evidence that radiotherapy is involved in the development of some of the excess of SPTs observed following childhood cancer; particularly following retinoblastoma and central nervous system tumours. This interpretation is supported by the following: the histological types of SPTs observed; the proportion of SPTs developing within tissue directly irradiated to treat the FPT; the intervals between radiotherapy and diagnosis of the SPTs.
Although there is substantial evidence from these studies of a relationship between radiotherapy and an increased risk of SPTs there is comparatively little evidence available on the risk associated with chemotherapy given to treat cancer in children. At present, within our cohort the average follow-up times beyond three years are short following chemotherapy except among retinoblastoma survivors. However, some indication of what may emerge in future analyses may be obtained from the accompanying paper (Kingston et al., 1987) , since this contains cases excluded from the cohort analysis because either the FPT or SPT occurred too recently for inclusion. We note here only that there is evidence that types of FPT and SPT observed appear to be changing, in that among individuals with their FPT diagnosed since 1970 the number of survivors subsequently developing leukaemia has increased substantially, the increase being spread across several FPT types including central nervous system tumours, acute leukaemia and lymphoma. This period corresponds to the increasing use of intensive multiple agent chemotherapy and it is tempting to consider chemotherapy as a cause. This might be indirect for instance as a result of immunosuppression, or because chemotherapy provided sufficient survival time for SPTs to emerge as a result of a mechanism not directly involving the chemotherapy, for example inherent predisposition (Penn, 1982) .
A recent paper by the LESG (Tucker et al., 1985a) reports an excess of second primary leukaemia within a cohort of individuals surviving at least two years from diagnosis of childhood cancer (0=22, E= 1.52, O/E= 14, 95%CI=(9, 22)). To determine if the increased risk was related to therapy a case-control study was carried out. No increase in risk was associated with radiotherapy. However, there was a significant relationship between dose of alkylating agents and the relative risk of secondary leukaemia, the relative risk reaching about twenty for the high (alkylating agent) dose categories. They conclude that the excess risk of secondary leukaemia following childhood cancer was almost entirely due to alkylating agents.
Genetic predisposition to multiple primary tumours exists among the survivors of genetic retinoblastoma, and the individuals with neurofibromatosis or Gorlin's (basal cell naevus) syndrome who developed a FPT of the central nervous system followed by a variety of SPTs. Among the survivors of genetic retinoblastoma there was an inherent risk of SPTs about thirteen-fold that expected from general population rates of cancer; the inherent risk of osteosarcoma exceeding 174-fold expected. After all first primary tumours except retinoblastoma, considered as one group, there was an inherent risk of a subsequent malignant tumour about four-fold expected.
Second primary tumours following retinoblastoma In our study the overall relative risk of a SPT was about 30 following genetic retinoblastoma, observed malignant bone tumours being more than 400-fold expected. There was evidence of an increased risk of SPT generally and osteosarcomas in particular following radiotherapy for genetic retinoblastoma compared to the inherent risk. There is some evidence of an increased risk of SPT associated with the use of cyclophosphamide, though it is not possible to be sure whether this is due to cyclophosphamide alone or radiotherapy or an interaction between them.
From a series of individuals on file at the Ophthalmic Oncology Center of the New York Hospital, Cornell Medical Center, a report (Abramson et al., 1984) gives risks of 20%, 50% and 90% at 10, 20 and 30 years from diagnosis of genetic retinoblastoma respectively; also reported are risks of second tumours in patients treated without radiotherapy or where tumours developed outside the radiation field of 10%, 30% and 68% at 10, 20 and 32 years from diagnosis respectively. These cumulative risks are an order of magnitude greater than estimated from our series, and it is very hard to explain the large discrepancy. However, we are satisfied that we have not missed a substantial number of SPTs within our cohort. Another large series is part of the LESG report (Tucker et al., 1984) , where 319 two-year survivors of retinoblastoma have been followed-up for an average period of seven years. No separation of unilateral and bilateral cases was carried out; the overall relative risk of a second primary was about 60; bone tumours were 1,000-fold expected.
Second primary bone tumours following childhood cancer other than retinoblastoma After all first primary tumours except retinoblastoma, considered as one group, the number of malignant bone tumours observed was eighteen-fold expected. Eight were osteosarcomas, one a fibrosarcoma and one an unspecified malignant tumour. Six of the bone tumours arose within directly irradiated tissue. The LESG has reported results from a case-control study of the involvement of radiotherapy and chemotherapy in the development of second primary bone cancer following childhood cancer (Tucker et al., 1985b) . In both retinoblastoma and other patients, the relative risk increased with increasing radiation dose, reaching a value of almost 40 at doses over 50 Gy. Independently of radiotherapy, alkylating agents were associated with a significant two-fold risk of bone cancer in both retinoblastoma and other patients.
Second primary CNS tumours following childhood cancer other than retinoblastoma The number of second primary malignant CNS tumours observed was about seven-fold expected. The presence of an increased inherent risk among survivors of childhood cancer is in line with the report of an increased likelihood of CNS tumours, leukaemia, and childhood tumours in relatives of children with CNS neoplasms (Farwell & Flannery, 1984b) . Several familial cancer syndromes have been reported involving tumours of the CNS; two, Turcot's syndrome (Turcot et al., 1959; Todd et al., 1981) and the Li-Fraumeni syndrome (Li & Fraumeni, 1969; Li & Fraumeni, 1982; Birch et al., 1984) , are well documented. Meadows et al. (1977) Ron & Modan, 1984) there was an excess of thyroid cancer, 100-fold expected among those treated with radiotherapy but no chemotherapy.
In a series of 670 individuals diagnosed with a CNS neoplasm before age twenty, nine had another primary neoplasm either before or after the CNS primary (Farwell & Flannery. 1984a ). The expected number of neoplasms was 0.99, yielding a relative risk of about nine. Radiotherapy was identified as a possible contributing factor to the development of the SPT in four individuals.
SPTs after Wilms' tumour The LESG (Tucker et al., 1984) examined the observed and expected numbers of second primary cancers among 1,248 children surviving at least two years from diagnosis of Wilms' tumour: the relative risk of any subsequent cancer was 24. Relative risks were significantly raised for thyroid, bone, connective tissue, digestive tract, CNS and leukaemia.
Another large study of survivors of Wilms' tumour (Li et al., 1983) , was based on 487 individuals treated at the DanaFarber Cancer Institute and Children's Hospital of Boston. Thirty SPTs were observed: eleven malignant, sixteen benign and three border line neoplasms. The cumulative risk of a second tumour was 6% (SE =2%) by twenty years from diagnosis. All but one second malignant tumour arose within the prior radiotherapy field. Of the benign second tumours nine were within the radiotherapy field. Among those given radiotherapy the relative risk of a second cancer was fourteen.
The results from the Dana-Farber series are similar to those from our series, though the risks from the LESG series are much larger.
SPTs after leukaemia
No firm conclusions may yet be drawn concerning the SPT risk following leukaemia in our series, since the average follow-up period beyond three-year survival is only just over three years. The twenty-fold excess of CNS tumours is quite striking, though it is based on only three cases. These all arose in individuals treated with chemotherapy and CNS irradiation; we cannot infer that treatment was necessarily directly involved in their development, since we have no measure of the risk of SPT in the absence of therapy.
Conclusion
The rate of occurrence of SPT is low and the risk attributable to therapy is small when compared to the improvements in survival rates achieved by the use of these treatments. Our data confirm that the use of radiotherapy is associated with an increased risk of SPT. However, the risks of SPT in our data are almost always lower than those reported from series treated in the United States. It is possible that the lower frequency of SPT observed in our data may be accounted for, to some extent, by the use of less combination therapy and lower doses of radiotherapy in Britain. It is our intention to explore these international differences further in the future. It is important to continue to monitor survivors so that tumour and treatment combinations giving rise to particularly excessive frequencies of SPTs may be identified and alternative therapies examined to see whether comparable survivla may be achieved with reduced adverse late effects.
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